Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer

Chen, Jinn‐Shiun; Chen, Kuei-Tien; Fan, Wenchun; Yu, Jau‐Song; Chang, Yu‐Sun; Chan, Err–Cheng

doi:10.1515/cclm.2010.123

Cited by 26 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rohayem et al (14) established a strict cutoff of the mean + 3 SDs and their data lead to a higher positivity when the cutoff was set as the mean + 2 SDs. Chen et al (18) established the cutoff using different criteria (Yowden's index from receiver operating characteristic curve analysis: sensitivity, +; specificity, -1); therefore, healthy volunteers exhibited a higher positivity rate (percentage of pseudo-positive patients, 35.9%) compared to the results of our study (8.1%; 5/62; actual plotting data not shown).…”

Section: Discussioncontrasting

confidence: 50%

“…As regards the positivity of anti-survivin antibody, Rohayem et al (14) reported a relatively lower positivity rate (8.2%; 4/49) in patients with colorectal cancer using their ELISA protocol. By contrast, Chen et al (18) reported high positivity (sensitivity, 56.9%) in patients with colon cancer. This significant difference by different investigators is mainly attributed to the criteria for establishing a cutoff value.…”

Section: Discussionmentioning

confidence: 87%

“…We also previously reported that autoantibodies against survivin and livin were detected in patients with gastrointestinal, lung, breast and hepatic cancers (9)(10)(11)(12)(13). Other studies also reported survivin autoantibody positivity in various cancers (14)(15)(16)(17)(18). However, there have been no comprehensive studies establishing an ideal detection combination regarding IAPs and other tumor markers.…”

Section: Introductionmentioning

confidence: 92%

See 2 more Smart Citations

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Hosono

Goto

Kobayashi

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Autoantibodies against cancer-related antigens may be detected in the sera of patients with various types of cancer, although their clinical utility has not yet been established. In this study, we aimed to demonstrate the diagnostic relevance of autoantibody detection against inhibitor of apoptosis protein (IAP) family members in colon cancer, as compared to anti-p53 antibody, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9. We established an ELISA system using original recombinant proteins of IAP family members (survivin, livin and X-linked IAP) and measured the expression levels in the sera of 62 healthy donors, 250 patients with colon polyps (adenoma) and 176 patients with colon cancer. When the cutoff value was set as the mean value + 2 standard deviations in healthy donors, anti-survivin exhibited the highest positivity rate (24.4%) among IAP autoantibodies in cancer patients. Furthermore, the anti-survivin antibody exhibited a high positivity rate in early-stage carcinoma and adenoma. In the combination assay, reflecting the significantly high positivity rate of CEA in stage IV tumors, the positivity rate was highest when combining the detection of anti-survivin antibody and CEA in cancer patients (50.0%), indicating that this combination may not be useful for the diagnosis of early-stage cancers. By contrast, reflecting the complete independence of anti-survivin and anti-p53 antibodies, the combination of detecting these two antibodies resulted in the highest positivity rate (35.6%) in early-stage disease (stage 0-I). These results suggest that the combined measurement of anti-survivin and anti-p53 antibodies may be useful for the detection of early-stage colon cancer.

show abstract

Section: Discussioncontrasting

confidence: 50%

Section: Discussionmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Hosono

Goto

Kobayashi

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Auto-Abs are highly specific, stable, and handily detectable in small volumes of specimens with well-established secondary reagents. These advantages lead many efforts into discovery of auto-Abs as biomarkers for detection of various types of cancers, such as colorectal (10)(11)(12), breast (13)(14)(15), ovarian (16,17), lung (18)(19)(20), liver (21,22), and pancreatic (23,24) cancers. As for OSCC, five auto-Abs have been individually identified as serum biomarker candidates, including anti-p53 (25)(26)(27)(28), anti-survivin (29,30), anticytokeratin 8 (CK-8; ref.…”

Section: Introductionmentioning

confidence: 99%

Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma

Chang

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Background: Oral cavity squamous cell carcinoma (OSCC) is one of the most common cancers worldwide, and its incidence is still increasing. Approximately 50% of patients with OSCC die within 5 years after diagnosis, mostly ascribed to the fact that the majority of patients present advanced stages of OSCC at the time of diagnosis.Methods: To discover salivary biomarkers for ameliorating the detection of OSCC, herein, we developed a multiplexed bead-based platform to simultaneously detect auto-antibodies (auto-Abs) in salivary samples.Results: Compared with healthy individuals, the salivary levels of anti-p53, anti-survivin, anti-Hsp60, and anti-RPLP0 were significantly elevated in patients with OSCC. Noteworthily, the elevated levels of anti-p53, anti-survivin, and anti-Hsp60 were already observed in individuals with oral potentially malignant disorder. Moreover, the salivary levels of anti-p53, anti-survivin, anti-Hsp60, anti-RPLP0, and anti-CK8 were significantly elevated in patients with early-stage OSCC compared with those in healthy individuals. Most importantly, the use of a combined panel of salivary anti-p53, anti-survivin, anti-Hsp60, and anti-RPLP0 largely improves the detection of OSCC.Conclusion: Collectively, our results reveal that the salivary auto-Abs are effective OSCC biomarkers and the four-auto-Ab panel provides a novel and practicable approach for OSCC screening.Impact: This study provides the first evidence for the potential clinical application of salivary auto-Abs in OSCC diagnosis. Cancer Epidemiol Biomarkers Prev; 23(8); 1569-78. Ó2014 AACR.

show abstract

“…Tumors may, e.g., induce the formation of specific antibodies, such as antibodies against HER-2 in patients with breast cancer [72] . There are reports indicating that the detection of autoantibodies in patients with cancer could be useful diagnostically as demonstrated for anti-survivin antibodies in patients with colorectal cancer [73] . Interestingly, the presence of autoimmune response may be a positive prognostic factor, e.g., the presence of anti-thyroid peroxidase antibodies in patients with breast cancer [74] .…”

Section: Detection Of the Host Response Against Tumormentioning

confidence: 99%

Laboratory medicine and medical oncology: the tale of two Cinderellas

Melichar

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Cancer represents a leading cause of death in the developed countries. The past 50 years have witnessed major progress in both laboratory medicine and clinical oncology that has translated into improved prognosis of cancer patients. From the humble beginnings as unrelated specialties, major advances in the understanding of molecular bases of cancer progression led to increased interactions between laboratory medicine and clinical (mostly medical) oncology. Laboratory medicine is now an integral part of the management of cancer patients. The many aspects of the role of laboratory medicine in clinical oncology include the determination of biomarkers that are used in establishing the diagnosis, predicting response to therapy or prognosis, study of the host response to tumor growth, detection of treatment toxicity and determining the concentrations of anticancer drugs.

show abstract

Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer

Abstract: A positive association between autoantibodies against survivin and preoperative CEA concentrations in sera of patients with CRCs was established. Our results suggest that analysis of both parameters would assist in screening patients with CRC.

Cited by 26 publications

References 25 publications

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Salivary Auto-Antibodies as Noninvasive Diagnostic Markers of Oral Cavity Squamous Cell Carcinoma

Laboratory medicine and medical oncology: the tale of two Cinderellas

Contact Info

Product

Resources

About